Cas:146137-94-2 Methyl 6-iodo-1-benzothiophene-2-carboxylate manufacturer & supplier

Chemical Name:Methyl 6-iodo-1-benzothiophene-2-carboxylate

CAS.NO:146137-94-2

Synonyms:methyl 6-iodobenzo[b]thiophene-2-carboxylate;6-IODO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID METHYL ESTER;Benzo[b]thiophene-2-carboxylicacid,6-iodo-,methyl ester

Molecular Formula:C₁₀H₇IO₂S

Molecular Weight:318.13100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:54.54000

Exact Mass:317.92100

LogP:3.29250

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like methyl 6-iodobenzo[b]thiophene-2-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzo[b]thiophene-2-carboxylicacid,6-iodo-,methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 6-iodobenzo[b]thiophene-2-carboxylate Use and application,Benzo[b]thiophene-2-carboxylicacid,6-iodo-,methyl ester technical grade,usp/ep/jp grade.

Related News: The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. Methyl 6-iodo-1-benzothiophene-2-carboxylate manufacturer The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. Methyl 6-iodo-1-benzothiophene-2-carboxylate supplier The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. Methyl 6-iodo-1-benzothiophene-2-carboxylate vendor The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. Methyl 6-iodo-1-benzothiophene-2-carboxylate factory In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday.